All News

PSA068.jpg

Expert Panel Guidance on Managing Psoriatic Arthritis and Comorbidities

d Jack Cush, MD

An expert panel has published their consensus guidelines for the management of psoriatic arthritis (PsA) and it's comorbidities in the journal Rheumatology. 

Read Article
joint.pain_.hand_.PIP_.jpg

Chronic MSK Pain and Earlier Retirement

d Jack Cush, MD

Frequent musculoskeletal pain is linked with an increased risk of exiting work and retiring earlier, according to a new study published in the journal PLOS ONE.

Read Article
IVF.jpg

Infection and Rituximab-linked Immunoglobulin Deficiency

d Jack Cush, MD

A minority of immune-mediated inflammatory disease (IMID) patients treated with rituximab (RTX) are expected to develop and depressed immunoglobulin (Ig) levels.  A recent cohort analysis suggests that RTX-induced Ig deficiency was not associated with an increased risk of severe infecti

Read Article
Heel, pain,enthesitis,achilles

Washington Post: Case of Delayed Rheum Diagnosis

d Jack Cush, MD

The Washington Post recently published a "medical mystery" case titled, "Medical Mysteries: A rolled ankle set this runner down a painful path", which tells the tale of how and why rheumatologists are often not consulted or are consulted too late.

Read Article
price%20dollar%20pill.jpg

Top 10 Pharma R&D Budgets in 2023

d Jack Cush, MD

Pharma budgets have undergone significant changes coming out of COVID. This year Merck & Co. has knocked Roche from previous years of leading in research and development (R&D) budgets and investments.

Read Article
Sleep.fatigue.doctor.jpg

Insights on Postinfectious ME/CFS

d Jack Cush, MD

The medical community is challenged by myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS - its origins, pathogenesis outcomes and treatment.  JAMA has reviewed a recent Nature paper wherein an NIH led team of multidisciplinary experts performed an inpatient study of postinfe

Read Article
Series of Chronic Cutaneous Lupus responding to anifrolumab. 6 pts (4 DLE, 2 CCLE) betw 37-66 yrs old w/ Dz duration 10.5 yrs, 4 w/ SLE, all refractory to multiple therapies Rx w/ ANIF w/ Skin benefit. 1 developed herpes, 1 had worsening of nephritis https://t.co/XF8uW5xR66 https://t.co/hIJi94uRvr

Links:

Dr. John Cush RheumNow ( View Tweet)
We're gearing up for Tuesday Night Rheumatology all April long. Register today! Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. https://t.co/TTMK07Bf7u https://t.co/lSxmfXI4sD

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 10 Pharma R&D Budgets in 2023 Pharma budgets have undergone significant changes since COVID. This year Merck & Co. has knocked Roche from previous years of leading in R&D budgets and investments. https://t.co/xx0eKgXaiQ https://t.co/tMrFlatoMk

Links:

Dr. John Cush RheumNow ( View Tweet)
Insights on Postinfectious ME/CFS JAMA has reviewed a recent Nature paper wherein an NIH led team of multidisciplinary experts performed an inpatient study of postinfectious ME/CFS patients. https://t.co/3NiJCqZVy0 https://t.co/GAoBW9U1DW

Links:

Dr. John Cush RheumNow ( View Tweet)
91 #SLE pts w/ no baseline synovitis, underwent Ultrasound exams. 10 yrs later, 31 had clinical progression of arthritis. Pts w/ progression, 75% had baseline subclinical synovitis on US vs without progression 77% did NOT have an abnormal US at baseline https://t.co/MN9wkNgsQV https://t.co/ozgvjFI531

Links:

Dr. John Cush RheumNow ( View Tweet)
Biden signs executive order on womens health research ($200 million to NIH interdisc. women res), focus on: - integrate Women’s Health Across Federal Research prgs - fund Research on Women’s Midlife Health - double funding Office Womens Health Research https://t.co/NKtI5iFKeb https://t.co/G5T0YEdEkO

Links:

Dr. John Cush RheumNow ( View Tweet)
Ides of March (3.15.2024) Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus. https://t.co/s87j9fXQNA https://t.co/QNDXweNAvp

Links:

Dr. John Cush RheumNow ( View Tweet)
4873 gout pts w/ High SUA renally typed: UA overproduct. (ROA 9%); underexcreter (RUE 61%); combined (23%) or normal (7%) ROL: older, lower SUA, tophi & DM RUE: lower BMI, No DM Combined: younger, HighBMI/SUA/eGFR & smoking Normal: older, Low SUA/eGFR https://t.co/9u0Lujlkqf https://t.co/gVOvwd54Z1

Links:

Dr. John Cush RheumNow ( View Tweet)
UAB study shows the US adult rheumatology workforce grew clinically active adult rheumatology workforce grew 23% betw 2009-2020; including a 43% increase in women. Number of Rheums (5,667) grew 23% and APPs (379) grew 141%. https://t.co/sVPoNIUZUu https://t.co/4myGYaUtcd

Links:

Dr. John Cush RheumNow ( View Tweet)
US Trends in RA DMARD Use 2017-2021 A trend analysis of disease-modifying anti-rheumatic drugs (DMARDs) shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. https://t.co/vQmVyAjIaL https://t.co/tSJ4H5XtnU

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR: Vaccination and Multisystem Inflammatory Syndrome in Children MIS-C is a rare but serious condition typically occurring 2–6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement. https://t.co/PN2MPQxqSR https://t.co/eIzB4pjner

Links:

Dr. John Cush RheumNow ( View Tweet)
In RA, NO selective response with Seropositivity. Study of 28 eligible RCTs shows pts Rx w/ cs- or bDMARD that seropositivity did not predict better bDMARD response (ACR20 RRR ~1). Comparable resp in RF+ & RF- w/ TNFi or non-TNFi bDMARDs. https://t.co/AUWPgkzayt https://t.co/om9AYhNsQ9

Links:

Dr. John Cush RheumNow ( View Tweet)
9 Facts about Leflunomide Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. https://t.co/X9lyrOs3D7 https://t.co/TGh2LnGdJ8

Links:

Dr. John Cush RheumNow ( View Tweet)
Retro study 109 oligoarticular JIA pts (~8 yrs) Rx w/ intraarticular steroids w/ 4.3 yrs F/U: 38% needed no Rx, 15.5% needed more IAS; 46% systemic Rx(MTX; 8 mos) &22% biologics(2.2 yrs later). @FUV 89% were inactive. Persistence predicted by ANA+ & B27+ https://t.co/5YLkYyA84l https://t.co/wClhEiKOIw

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×